Global Information
회사소개 | 문의

유럽 생명과학 공급망의 디지털 전환 : 효율, 안전성, 투명성을 실현

Digital Transformation in the European Life Sciences Supply Chain: Enabling Efficiency, Safety, and Transparency

리서치사 IDC
발행일 2018년 06월 상품 코드 655492
페이지 정보 영문 12 Pages
US $ 4,500 ₩ 5,081,800 PDF by E-mail (Single User License)

유럽 생명과학 공급망의 디지털 전환 : 효율, 안전성, 투명성을 실현 Digital Transformation in the European Life Sciences Supply Chain: Enabling Efficiency, Safety, and Transparency
발행일 : 2018년 06월 페이지 정보 : 영문 12 Pages

유럽의 생명과학 기업은 FMD나 IDMP 등 예정된 규제에 대처하기 위해 트레이서빌리티(Traceability) 및 정보 관리 솔루션에 투자할 필요가 있습니다.

공급망 전환에서 기술의 역할에 초점을 맞추어 제3플랫폼 기술과 혁신 촉진요인(클라우드, 모바일, 빅데이터 애널리틱스, IoT 등)의 잠재성에 대해 분석하여 전해드립니다.

1. 주요 요약

2. 상황 개요

  • 유럽의 생명과학 공급망 전환 : 행동을 요청
    • 생명과학 공급망 전환
    • 생명과학 공급망용 신규 디지털 플랫폼

3. 기술 바이어에 대한 제안

  • 컴플라이언스를 넘어 : 과제는 기회로

4. 참고 자료

  • 관련 조사
  • 요약
KSM 18.07.04

This IDC Perspective examines the role of technology in supply chain transformation, discussing the potential of 3rd Platform technologies and Innovation Accelerators (e.g., cloud, mobile, Big Data analytics, and IoT) to support the critical aspects of supply chain performance, leading to improved safety and reliability, transparency, and efficiency. This study also provides essential guidance for life sciences manufacturers and their supply chain partners that wish to embark on a digital journey for their supply chain transformation in European markets. "European life sciences companies need to invest in traceability and information management solutions to avoid delays and penalties related to upcoming regulations such as FMD and IDMP. However, they should also make sure these investments are part of a wider supply chain digital transformation, looking beyond pure compliance and prioritizing initiatives that consider the transition toward new outcome-based business models," said Silvia Piai, senior research manager, IDC Health Insights. "Never before has the pharmaceutical industry had an opportunity to gain a holistic, 360-degree view of and control over their supply chains through 3rd Platform technologies.""European life sciences companies should capitalize on this opportunity to turn their supply chains into a source of competitive advantage," added Nino Giguashvili, senior research analyst, IDC Health Insights.

Executive Snapshot

Situation Overview

  • Life Sciences Supply Chain Transformation in Europe: A Call for Action
    • Life Sciences Supply Chain Transformation: The Pressure Is Real
      • Evolving Regulations Call for Improved Safety and Transparency of Supply Chains
      • Innovative Products in the R&D Pipeline Call for New Manufacturing and Distribution Models
      • Value-Based Healthcare Models Call for Agile and Efficient Supply Chains
      • Neglecting Supply Chain Optimization Already Affects the Whole Company
    • The New Digital Platform for Life Sciences Supply Chains
      • Three Areas of Impact and Performance Dimensions
      • An Intelligent Core for Life Sciences Digital Transformation
        • The Next Generation Life Sciences Supply Chain Platform is Cloud Native
        • Transparency, Automation at the Asset Level Through IoT
        • Cold Chain Management
        • Building Trust: Next-Generation Security as a Competitive Advantage
        • Transforming Information into Action, Mitigating Risks: The Role of Big Data and Analytics, Artificial Intelligence

Advice for the Technology Buyer

  • Beyond Compliance: Challenge Becomes an Opportunity

Learn More

  • Related Research
  • Synopsis
Back to Top
전화 문의